KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Enterprise Value (2016 - 2025)

NovoCure's Enterprise Value history spans 12 years, with the latest figure at -$447.7 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 53.36% year-over-year to -$447.7 million; the TTM value through Dec 2025 reached -$447.7 million, up 53.36%, while the annual FY2025 figure was -$447.7 million, 53.36% up from the prior year.
  • Enterprise Value for Q4 2025 was -$447.7 million at NovoCure, down from -$344.6 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$157.5 million in Q2 2023 and bottomed at -$970.3 million in Q3 2022.
  • The 5-year median for Enterprise Value is -$794.9 million (2021), against an average of -$637.5 million.
  • The largest YoY upside for Enterprise Value was 64.1% in 2025 against a maximum downside of 441.15% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$209.6 million in 2021, then crashed by 362.49% to -$969.4 million in 2022, then increased by 6.07% to -$910.6 million in 2023, then fell by 5.41% to -$959.9 million in 2024, then skyrocketed by 53.36% to -$447.7 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Enterprise Value are -$447.7 million (Q4 2025), -$344.6 million (Q3 2025), and -$911.5 million (Q2 2025).